OBJECTIVE: We sought to determine the effect of neoadjuvant chemoradiotherapy followed by surgical intervention on health-related quality of life in patients with esophageal cancer. METHODS:Health-related quality of life was evaluated in a prospective phase II study of neoadjuvant chemoradiotherapy followed by esophagectomy in 52 patients with carcinoma of the esophagus. Esophagectomy was performed 6 weeks after completion of induction. Functional Assessment of Cancer Therapy-Esophageal scoring was performed before treatment, 7 weeks after initiation of neoadjuvant therapy, before resection, and at 1, 3, and 6 months and 1 year after resection. RESULTS: Forty-three patients completed the entire treatment protocol. Functional Assessment of Cancer Therapy-Esophageal scores decreased significantly after chemoradiation at week 7 (120 vs 127 at baseline, P = .04) but returned to baseline levels before surgical intervention (127). Similarly, scores decreased significantly after surgical intervention (115 at 1 month, P = .02) but returned to baseline levels by 3 months postoperatively (127). At 1 year postoperatively, there was a statistically significant improvement in scores compared with those at baseline (139, P = .003). Functional Assessment of Cancer Therapy-Esophageal scores continued to increase over time for patients who were alive at least 1 year after the operation with or without disease but were observed to significantly decrease in those who died within 1 year after the operation (P = .0001). An increase in quality of life was associated with a significantly lower risk of death (P = .04). CONCLUSION:Neoadjuvant therapy has a significant effect on health-related quality of life, but this is transient, with recovery to baseline within 5 to 7 weeks after completion of induction therapy. Health-related quality of life decreases again after surgical intervention but returns to baseline levels within 3 months.
RCT Entities:
OBJECTIVE: We sought to determine the effect of neoadjuvant chemoradiotherapy followed by surgical intervention on health-related quality of life in patients with esophageal cancer. METHODS: Health-related quality of life was evaluated in a prospective phase II study of neoadjuvant chemoradiotherapy followed by esophagectomy in 52 patients with carcinoma of the esophagus. Esophagectomy was performed 6 weeks after completion of induction. Functional Assessment of Cancer Therapy-Esophageal scoring was performed before treatment, 7 weeks after initiation of neoadjuvant therapy, before resection, and at 1, 3, and 6 months and 1 year after resection. RESULTS: Forty-three patients completed the entire treatment protocol. Functional Assessment of Cancer Therapy-Esophageal scores decreased significantly after chemoradiation at week 7 (120 vs 127 at baseline, P = .04) but returned to baseline levels before surgical intervention (127). Similarly, scores decreased significantly after surgical intervention (115 at 1 month, P = .02) but returned to baseline levels by 3 months postoperatively (127). At 1 year postoperatively, there was a statistically significant improvement in scores compared with those at baseline (139, P = .003). Functional Assessment of Cancer Therapy-Esophageal scores continued to increase over time for patients who were alive at least 1 year after the operation with or without disease but were observed to significantly decrease in those who died within 1 year after the operation (P = .0001). An increase in quality of life was associated with a significantly lower risk of death (P = .04). CONCLUSION: Neoadjuvant therapy has a significant effect on health-related quality of life, but this is transient, with recovery to baseline within 5 to 7 weeks after completion of induction therapy. Health-related quality of life decreases again after surgical intervention but returns to baseline levels within 3 months.
Authors: Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen Journal: Gastroenterology Date: 2011-03 Impact factor: 22.682
Authors: Lisa A Kachnic; Kathryn Winter; Todd Wasserman; David Kelsen; Robert Ginsberg; Thomas M Pisansky; James Martenson; Ritsuko Komaki; Gordon Okawara; Seth A Rosenthal; Christopher G Willett; Bruce D Minsky Journal: Gastrointest Cancer Res Date: 2011-03
Authors: Enrico M Minnella; Rashami Awasthi; Sarah-Eve Loiselle; Ramanakumar V Agnihotram; Lorenzo E Ferri; Francesco Carli Journal: JAMA Surg Date: 2018-12-01 Impact factor: 14.766
Authors: Inderpal S Sarkaria; Nabil P Rizk; Debra A Goldman; Camelia Sima; Kay See Tan; Manjit S Bains; Prasad S Adusumilli; Daniela Molena; Matthew Bott; Thomas Atkinson; David R Jones; Valerie W Rusch Journal: Ann Thorac Surg Date: 2019-04-23 Impact factor: 4.330
Authors: Hee-Jung Yoo; Sung-Bae Kim; Dok Hyun Yoon; Seung-Il Park; Jong-Hoon Kim; David Cella; Hwoon-Yong Jung; Gin-Hyug Lee; Kee Don Choi; Ho June Song; Ho Young Song; Ji Hoon Shin; Kyung-Ja Cho Journal: Qual Life Res Date: 2011-11-01 Impact factor: 4.147
Authors: Alla Alghamedi; Gordon Buduhan; Lawrence Tan; Sadeesh Kumar Srinathan; Joanne Sulman; Gail Darling; Biniam Kidane Journal: Ann Transl Med Date: 2018-02
Authors: Giorgio Diamantis; Marco Scarpa; Paolo Bocus; Stefano Realdon; Carlo Castoro; Ermanno Ancona; Giorgio Battaglia Journal: World J Gastroenterol Date: 2011-01-14 Impact factor: 5.742